[["about half of patients with papillary thyroid cancer", "have", "tumours with activating BRAF(V600E) mutations"], ["vemurafenib", "is an oncogenic", "BRAF kinase inhibitor approved for BRAF-positive melanoma"], ["vemurafenib", "showed clinical benefit in", "three patients with BRAF(V600E)-positive papillary thyroid cancer"], ["the aim of the study", "was to establish", "the activity of vemurafenib in patients with BRAF(V600E)-positive papillary thyroid cancer"], ["the trial", "was open-label, non-randomised, phase 2", "at ten academic centres and hospitals worldwide"], ["participants", "were aged", "18 years or older"], ["participants", "had", "histologically confirmed recurrent or metastatic papillary thyroid cancer"], ["participants", "were refractory to", "radioactive iodine"], ["participants", "were positive for", "the BRAF(V600E) mutation"], ["patients", "received", "vemurafenib 960 mg orally twice daily"], ["the primary endpoint", "was", "investigator-assessed best overall response in cohort 1"], ["analyses", "were planned to have", "a minimum median follow-up of 15 months"], ["51 patients", "were enrolled in", "the study"], ["median duration of follow-up in cohort 1", "was", "18.8 months"], ["median duration of follow-up in cohort 2", "was", "12.0 months"], ["partial responses", "were recorded in", "ten of 26 patients in cohort 1"], ["grade 3 or 4 adverse events", "were recorded in", "17 of 26 patients in cohort 1"], ["grade 3 or 4 adverse events", "were recorded in", "17 of 25 patients in cohort 2"], ["the most common grade 3 and 4 adverse events", "were", "squamous cell carcinoma of the skin, lymphopenia, and increased \u03b3-glutamyltransferase"], ["two individuals in cohort 2", "died due to", "adverse events"], ["neither death", "was", "treatment related"], ["serious adverse events", "were reported for", "16 of 26 patients in cohort 1"], ["serious adverse events", "were reported for", "17 of 25 patients in cohort 2"], ["vemurafenib", "showed", "antitumour activity in patients with progressive, BRAF(V600E)-positive papillary thyroid cancer"], ["vemurafenib", "represents", "a potential new treatment option for these patients"], ["F Hoffmann-La Roche", "provided", "funding for the study"]]